9.6 Side Effects
The ophthalmologist is faced with considerable challenges when treating DME patients with anti-VEGF agents. According to a review by Blumenkranze et al., the correlation between baseline best corrected visual acuity (BCVA) and macular thickness in patients with persistent macular edema is only modest. Numerous factors can influence visual function in eyes with DME, including the morphologic pattern of edema (focal or diffuse), duration of retinal edema, retinal perfusion, total retinal volume, and vitreomacular interface abnormalities (posterior hyaloidal traction, epiretinal membrane, and serous or tractional retinal detachment). Newer imaging technologies, such as swept-source optical coherence tomography and ultra-widefield angiography) are being developed to improve the clinician’s ability to observe morphologic changes to the retina and assess treatment efficacy and safety.
Quiz Module 9.6
To validate your answers and keep track of your progress please sign in or register a new account
1. Which of the following is not a factor in visual function for patient with DME?
2. What percentage(s) of patients have been shown to experience clinically relevant increases in visual acuity with anti-VEGF agents?
3. There is a high correlation between baseline best corrected visual acuity (BCVA) and macular thickness in patients with persistent macular edema.
4. With regard to anti-VEGF agents: